BIIB
What one share of Biogen holds
Biological Products, (No Diagnostic Substances)
Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer’s disease and launched the first approved treatment to target a genetic cause of ALS.
Biogen’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-03-31; the balance sheet is as of 2026-03-31.
| Sales | $67.35 |
|---|---|
| Profit | $9.30 |
| Capex (buildings and equipment) | $1.14 |
| Free cash flow | $16.42 |
| Cash and investments | $22.91 |
| Debt | $42.59 |
| Book value | $126.33 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2007 | $9.91 | $1.99 | $0.89 | $2.29 | — | $17.59 |
| 2008 | $13.89 | $2.65 | $0.94 | $4.36 | — | $20.16 |
| 2009 | $15.12 | $3.35 | $0.57 | $3.14 | — | — |
| 2010 | $18.51 | $3.94 | $0.68 | $5.70 | — | $22.44 |
| 2011 | $20.60 | $5.04 | $0.85 | $6.20 | — | $26.54 |
| 2012 | $23.01 | $5.76 | $1.06 | $6.78 | — | $29.43 |
| 2013 | $29.09 | $7.81 | $1.03 | $8.81 | — | $36.48 |
| 2014 | $40.91 | $12.37 | $1.21 | $11.19 | — | $46.07 |
| 2015 | $46.56 | $15.34 | $2.78 | $14.17 | — | $42.88 |
| 2016 | $52.33 | $16.92 | $2.82 | $18.15 | — | $56.23 |
| 2017 | $57.62 | $11.92 | $4.07 | $17.29 | — | $59.63 |
| 2018 | $65.53 | $21.58 | $3.75 | $26.39 | — | $66.12 |
| 2019 | $76.72 | $31.42 | $2.75 | $35.03 | — | $76.60 |
| 2020 | $83.35 | $24.80 | $2.63 | $23.59 | — | $70.21 |
| 2021 | $73.41 | $10.40 | $1.73 | $22.61 | — | $74.12 |
| 2022 | $69.68 | $20.87 | $1.65 | $7.84 | — | $93.04 |
| 2023 | $67.55 | $7.97 | $1.90 | $8.72 | — | $102.14 |
| 2024 | $66.32 | $11.19 | $1.05 | $18.66 | — | $114.65 |
| 2025 | $67.24 | $8.79 | $1.05 | $13.94 | — | $124.37 |